---
title: "BLTE.US (BLTE.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/BLTE.US/news.md"
symbol: "BLTE.US"
name: "BLTE.US"
parent: "https://longbridge.com/zh-CN/quote/BLTE.US.md"
datetime: "2026-03-12T04:12:05.678Z"
locales:
  - [en](https://longbridge.com/en/quote/BLTE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BLTE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BLTE.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/BLTE.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BLTE.US/news.md)


# BLTE.US (BLTE.US) — 相关新闻

### [Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference](https://longbridge.com/zh-CN/news/278557647.md)
*2026-03-10T12:38:00.000Z*
> Belite Bio (NASDAQ:BLTE) presented results from its Phase 3 DRAGON trial at a conference, showing that its drug Tinlareb

### [Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright](https://longbridge.com/zh-CN/news/278094789.md)
*2026-03-06T12:13:28.000Z*
> HC Wainwright has revised its Q1 2026 EPS estimate for Belite Bio, lowering it from ($0.56) to ($0.71). The firm maintai

### [Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win](https://longbridge.com/zh-CN/news/277455527.md)
*2026-03-02T11:35:46.000Z*
> Belite Bio, Inc. reported preliminary fourth-quarter and full-year 2025 results, highlighting a pivotal year for its lea

### [Belite Bio FY Net Income USD -77.611 Million](https://longbridge.com/zh-CN/news/277450424.md)
*2026-03-02T11:00:46.000Z*
> Mar 02 (Reuters) - Belite Bio FY operating expenses USD 84.208 million. * FY pretax profit USD -77.611 million * FY inco

### [Exploring Belite Bio's Earnings Expectations](https://longbridge.com/zh-CN/news/277224746.md)
*2026-02-27T16:00:51.000Z*
> Belite Bio (NASDAQ:BLTE) will report its quarterly earnings on March 2, 2026, with analysts estimating an EPS of $-0.55.

### [Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January](https://longbridge.com/zh-CN/news/275979339.md)
*2026-02-14T12:36:49.000Z*
> Belite Bio, Inc. (NASDAQ:BLTE) experienced a 49.4% increase in short interest in January, totaling 585,301 shares as of 

### [Taiwan Stock Market Update: Qihong's stock price rises, Yanqin launches facial recognition APP, Renxin Biotechnology makes significant progress, AI technology drives corporate transformation](https://longbridge.com/zh-CN/news/273928271.md)
*2026-01-28T03:20:09.000Z*
> The dynamics of the Taiwan stock market show that the stock price of Qihong surged due to increased demand for NVIDIA pr

### [Renxin LBS-008 Sturge-Weber Syndrome DRAGON II Phase II/III trial completed enrollment](https://longbridge.com/zh-CN/news/273910651.md)
*2026-01-28T00:43:01.000Z*
> Renxin (6696) subsidiary Belite Bio, Inc. announced that the DRAGON II Phase II/III clinical trial for LBS-008 targeting

### [Belite Bio Completes Enrollment in Phase 2/3 DRAGON II Trial for Stargardt Disease](https://longbridge.com/zh-CN/news/273873856.md)
*2026-01-27T17:09:24.000Z*
> Belite Bio Inc. has completed enrollment in the Phase 2/3 DRAGON II trial for tinlarebant, aimed at treating Stargardt d